Q-omics provides the consensus-scored MIR4526 profile across patient tissues and cancer cell-line models. MIR4526 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MIR4526 is differentially expressed in 6, with the highest sampling consensus in BRCA. Additionally, MIR4526 RNA expression shows 10,023 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight ACC, and BRCA as cancer lineages where MIR4526 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4526 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4526 survival associations across molecular data types. MIR4526 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4526 RNA expression–survival associations across cancer types. High MIR4526 expression shows unfavorable associations in ACC, CESC, MESO, READ and BLCA, but favorable associations in ESCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MIR4526 RNA expression.
This table summarizes MIR4526 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4526. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4526 shows lower tumor expression in LUSC and higher tumor expression in BRCA, KIRC, ESCA, HNSC and LIHC. The BRCA box plot shows higher MIR4526 RNA expression in tumor versus normal tissue (log2 FC = +0.968, t-test p < 0.001).
This table shows molecular features associated with MIR4526 in patient tissues and cancer cell lines. In patient samples, MIR4526 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
